Items Tagged ‘Verzenio’

March 12, 2018

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases […]

View full entry

Tags: 4 & 6, Breast Cancer, CDK, inhibitor of cyclin-dependent kinases, News, Verzenio


October 30, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

By

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio


October 5, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers

By

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio